Royal Bank of Canada
RXRX icon

Royal Bank of Canada’s Recursion Pharmaceuticals RXRX Stock Holding History

Royal Bank of Canada’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7K Sell
2,595
-97,164
-97% -$375K ﹤0.01% 6333
2025
Q4 		$409K Buy
99,759
+31,566
+46% +$156K ﹤0.01% 4317
2025
Q3 		$333K Sell
68,193
-332,928
-83% -$1.75M ﹤0.01% 4767
2025
Q2 		$2.03M Buy
401,121
+132,108
+49% +$649K ﹤0.01% 3289
2025
Q1 		$1.42M Buy
269,013
+232,038
+628% +$1.69M ﹤0.01% 3201
2024
Q4 		$250K Sell
36,975
-8,357
-18% -$56.2K ﹤0.01% 4627
2024
Q3 		$299K Sell
45,332
-4,403
-9% -$31.6K ﹤0.01% 4509
2024
Q2 		$373K Buy
49,735
+34,126
+219% +$298K ﹤0.01% 4244
2024
Q1 		$155K Sell
15,609
-18,456
-54% -$206K ﹤0.01% 4898
2023
Q4 		$336K Buy
34,065
+7,900
+30% +$56.3K ﹤0.01% 4629
2023
Q3 		$200K Buy
26,165
+11,676
+81% +$116K ﹤0.01% 4805
2023
Q2 		$108K Buy
14,489
+6,581
+83% +$46K ﹤0.01% 5272
2023
Q1 		$53K Sell
7,908
-14,501
-65% -$115K ﹤0.01% 5593
2022
Q4 		$172K Buy
22,409
+20,462
+1,051% +$201K ﹤0.01% 5006
2022
Q3 		$21K Buy
1,947
+935
+92% +$9.47K ﹤0.01% 6119
2022
Q2 		$8K Sell
1,012
-6,069
-86% -$40.6K ﹤0.01% 6479
2022
Q1 		$51K Sell
7,081
-17,722
-71% -$188K ﹤0.01% 6084
2021
Q4 		$425K Buy
24,803
+21,954
+771% +$413K ﹤0.01% 4615
2021
Q3 		$65K Buy
2,849
+1,404
+97% +$39.8K ﹤0.01% 5997
2021
Q2 		$53K Buy
+1,445
New +$42.8K ﹤0.01% 6001

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada's RXRX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Recursion Pharmaceuticals (RXRX) stake by 97% in Q1 2026, selling an estimated $375K and leaving 2,595 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #6333.

Royal Bank of Canada first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $2.03M in Q2 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Royal Bank of Canada held 2,595 shares of Recursion Pharmaceuticals worth $7K as of Q1 2026.
  • Royal Bank of Canada sold 97,164 Recursion Pharmaceuticals shares in Q1 2026, an estimated $375K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6333 holding.
  • Royal Bank of Canada first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Royal Bank of Canada's Recursion Pharmaceuticals position peaked at $2.03M in Q2 2025.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.